Tributyrin for Health & Longevity - Quick Reference Sheet

Tributyrin for Health & Longevity

Created on 07/23/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Tributyrin is a natural butter fat that delivers butyrate, a beneficial fatty acid, to the gut in a slower, steadier, sodium-free way than butyrate salts, while shifting gut bacteria toward a healthier balance. Broader benefits for inflammation, metabolism, the brain, and longevity remain unproven in people. Low-risk and well-tolerated; best alongside a fiber-rich diet. (Full Review)

Protocol

Dose
500 mg–2 g/day
Typically divided and taken with meals
Timing
With meals
A fat-containing meal enables lipase-mediated conversion
Dosing schedule
Split 2–3×/day
Smooths delivery; once-daily acceptable at lower doses
Time to effect
Butyrate delivery
~52 min
Peak plasma butyrate after a dose
Gut & inflammation
~3 weeks
Microbiome and inflammatory changes with daily use
Metabolic effects
Longer
Expected to take longer; unproven in humans

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Significant exocrine pancreatic insufficiency
  • Known formulation hypersensitivity
Key Interactions
  • Valproate or HDAC inhibitors (vorinostat, romidepsin)
  • Orlistat / lipase-blocking agents
  • Lipase or fat-blocking supplements
  • Other butyrate sources, resistant starch, prebiotics

Risk & Side Effects

  • High: Gastrointestinal discomfort
  • Medium: Unpalatable taste and malodorous burping
  • Low: Additive effect with other HDAC-inhibiting agents
  • Speculative: High-dose cytotoxicity and off-target epigenetic effects; unknown long-term safety in healthy adults

Monitoring

Marker Target Why
hs-CRP < 0.5 mg/L Tracks systemic inflammation, a proposed tributyrin target
Fasting glucose 75–90 mg/dL Baseline glucose control
HbA1c < 5.4% Average blood sugar over ~3 months
Fasting insulin / HOMA-IR Insulin 2–5 µIU/mL; HOMA-IR < 1.5 Insulin sensitivity
Triglycerides < 80 mg/dL Metabolic and lipid status
Fecal calprotectin < 50 µg/g Gut mucosal inflammation

Cadence: Baseline, then 4–8 weeks after starting, then every 6–12 months if used long-term

Qualitative Assessment

  • Digestive comfort, stool regularity and form, and bloating
  • Tolerability of the dose (nausea, taste, burping)
  • Energy levels and post-meal comfort
  • Subjective changes in cognitive clarity or mood